Suppr超能文献

[肝硬化中肝细胞癌的流行病学与诊断]

[Epidemiology and diagnosis of hepatocellular carcinomas in cirrhosis].

作者信息

Duvoux C

机构信息

Service d'Hépatologie et de Gastroentérologie, Hôpital Henri-Mondor, Créteil.

出版信息

Ann Chir. 1998;52(6):511-7.

PMID:9752500
Abstract

Hepatocellular carcinoma (HCC) is the most frequent primary cancer of the liver and the most frequent tumour in males, worldwide. The annual incidence of HCC is maximum in Asian and African countries, lower in western countries where it is close to 4/100,000 inhabitants. In 90% of the cases, HCC complicates course of liver cirrhosis, with an annual incidence in cirrhoties of 2 to 6%. Risk factors for HCC in cirrhotics are male gender (sex-ratio: 4/1), age (above 50 years old), macronodular cirrhosis and large cell dysplasia. HCC can complicate the course of cirrhosis of any cause, but might be less frequent in primary biliary cirrhosis, Wilson's disease and auto-immune hepatitis. Currently, the diagnosis of HCC is usually considered in the presence of a focal nodular lesion, during systematic ultrasonographic examination of the liver. In high incidence areas, HCC can still be diagnosed because of HCC-related symptoms. In the case of a focal lesion discovered on a cirrhotic liver, the diagnosis of HCC can be confirmed by studying the behaviour of the lesion of helical CT scan of the liver (enhancement of the tumour during the arterial phase) or MRI (hyperintensity of the tumour on T2 relaxation time); study of peritumour vessels can also be helpful. Serum alpha-foeto-protein level, when higher than 300 to 500 micrograms/L is very specific of HCC. When aggressive treatment of HCC is considered and when the diagnosis of HCC remains uncertain, HCC can be assessed by means of cytological or histological study of the tumour on samples taken by fineneedle aspiration (80% sensitivity) or liver biopsy during laparoscopic laparotomy. Forthcoming improvements in imaging technology might eliminate the need for such invasive diagnostic techniques in the future.

摘要

肝细胞癌(HCC)是全球最常见的原发性肝癌,也是男性中最常见的肿瘤。HCC的年发病率在亚洲和非洲国家最高,在西方国家较低,接近每10万居民中有4例。在90%的病例中,HCC使肝硬化病程复杂化,肝硬化患者的年发病率为2%至6%。肝硬化患者发生HCC的危险因素包括男性(性别比:4/1)、年龄(50岁以上)、大结节性肝硬化和大细胞异型增生。HCC可使任何病因的肝硬化病程复杂化,但在原发性胆汁性肝硬化、威尔逊病和自身免疫性肝炎中可能较少见。目前,在对肝脏进行系统性超声检查时,通常在发现局灶性结节性病变的情况下考虑诊断HCC。在高发地区,仍可因HCC相关症状诊断出HCC。对于在肝硬化肝脏上发现的局灶性病变,可通过研究肝脏螺旋CT扫描(动脉期肿瘤强化)或MRI(肿瘤在T2弛豫时间上呈高信号)的病变表现来确诊HCC;研究肿瘤周围血管也可能有帮助。血清甲胎蛋白水平高于300至500微克/升时对HCC具有高度特异性。当考虑对HCC进行积极治疗且HCC诊断仍不确定时,可通过对细针穿刺获取的肿瘤样本(敏感性为80%)或腹腔镜剖腹术中的肝活检进行肿瘤的细胞学或组织学研究来评估HCC。未来成像技术的进一步改进可能会消除对这种侵入性诊断技术的需求。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验